Literature DB >> 33522391

Harnessing machine learning for development of microbiome therapeutics.

Laura E McCoubrey1, Moe Elbadawi1, Mine Orlu1, Simon Gaisford1,2, Abdul W Basit1.   

Abstract

The last twenty years of seminal microbiome research has uncovered microbiota's intrinsic relationship with human health. Studies elucidating the relationship between an unbalanced microbiome and disease are currently published daily. As such, microbiome big data have become a reality that provide a mine of information for the development of new therapeutics. Machine learning (ML), a branch of artificial intelligence, offers powerful techniques for big data analysis and prediction-making, that are out of reach of human intellect alone. This review will explore how ML can be applied for the development of microbiome-targeted therapeutics. A background on ML will be given, followed by a guide on where to find reliable microbiome big data. Existing applications and opportunities will be discussed, including the use of ML to discover, design, and characterize microbiome therapeutics. The use of ML to optimize advanced processes, such as 3D printing and in silico prediction of drug-microbiome interactions, will also be highlighted. Finally, barriers to adoption of ML in academic and industrial settings will be examined, concluded by a future outlook for the field.

Entities:  

Keywords:  COVID-19; artificial intelligence; clinical translation; colonic drug delivery; drug product development; machine learning; microbial therapeutics; microbiome; personalized medicines; pharmaceutical sciences

Mesh:

Year:  2021        PMID: 33522391      PMCID: PMC7872042          DOI: 10.1080/19490976.2021.1872323

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  151 in total

Review 1.  The gastrointestinal microbiota as a site for the biotransformation of drugs.

Authors:  Tiago Sousa; Ronnie Paterson; Vanessa Moore; Anders Carlsson; Bertil Abrahamsson; Abdul W Basit
Journal:  Int J Pharm       Date:  2008-07-16       Impact factor: 5.875

2.  Separating host and microbiome contributions to drug pharmacokinetics and toxicity.

Authors:  Michael Zimmermann; Maria Zimmermann-Kogadeeva; Rebekka Wegmann; Andrew L Goodman
Journal:  Science       Date:  2019-02-07       Impact factor: 47.728

Review 3.  Gut microbiome, big data and machine learning to promote precision medicine for cancer.

Authors:  Giovanni Cammarota; Gianluca Ianiro; Anna Ahern; Carmine Carbone; Andriy Temko; Marcus J Claesson; Antonio Gasbarrini; Giampaolo Tortora
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-09       Impact factor: 46.802

4.  Colonic bacterial metabolism of corticosteroids.

Authors:  Vipul Yadav; Simon Gaisford; Hamid A Merchant; Abdul W Basit
Journal:  Int J Pharm       Date:  2013-09-18       Impact factor: 5.875

5.  Computational Prediction of a New ADMET Endpoint for Small Molecules: Anticommensal Effect on Human Gut Microbiota.

Authors:  Suqing Zheng; Wenping Chang; Wenxin Liu; Guang Liang; Yong Xu; Fu Lin
Journal:  J Chem Inf Model       Date:  2018-11-07       Impact factor: 4.956

6.  Body Site Is a More Determinant Factor than Human Population Diversity in the Healthy Skin Microbiome.

Authors:  Guillermo I Perez Perez; Zhan Gao; Roland Jourdain; Julia Ramirez; Francesca Gany; Cecile Clavaud; Julien Demaude; Lionel Breton; Martin J Blaser
Journal:  PLoS One       Date:  2016-04-18       Impact factor: 3.240

7.  Fungal microbiota dysbiosis in IBD.

Authors:  Harry Sokol; Valentin Leducq; Hugues Aschard; Hang-Phuong Pham; Sarah Jegou; Cecilia Landman; David Cohen; Giuseppina Liguori; Anne Bourrier; Isabelle Nion-Larmurier; Jacques Cosnes; Philippe Seksik; Philippe Langella; David Skurnik; Mathias L Richard; Laurent Beaugerie
Journal:  Gut       Date:  2016-02-03       Impact factor: 23.059

8.  Distinct microbial and immune niches of the human colon.

Authors:  Kylie R James; Tomas Gomes; Rasa Elmentaite; Nitin Kumar; Emily L Gulliver; Hamish W King; Mark D Stares; Bethany R Bareham; John R Ferdinand; Velislava N Petrova; Krzysztof Polański; Samuel C Forster; Lorna B Jarvis; Ondrej Suchanek; Sarah Howlett; Louisa K James; Joanne L Jones; Kerstin B Meyer; Menna R Clatworthy; Kourosh Saeb-Parsy; Trevor D Lawley; Sarah A Teichmann
Journal:  Nat Immunol       Date:  2020-02-17       Impact factor: 25.606

9.  Efficacy of an Anthocyanin and Prebiotic Blend on Intestinal Environment in Obese Male and Female Subjects.

Authors:  Shelly N Hester; Angela Mastaloudis; Russell Gray; Joseph M Antony; Mal Evans; Steven M Wood
Journal:  J Nutr Metab       Date:  2018-09-13

10.  Extensive impact of non-antibiotic drugs on human gut bacteria.

Authors:  Lisa Maier; Mihaela Pruteanu; Michael Kuhn; Georg Zeller; Anja Telzerow; Exene Erin Anderson; Ana Rita Brochado; Keith Conrad Fernandez; Hitomi Dose; Hirotada Mori; Kiran Raosaheb Patil; Peer Bork; Athanasios Typas
Journal:  Nature       Date:  2018-03-19       Impact factor: 49.962

View more
  9 in total

1.  Differences in composition of interdigital skin microbiota predict sheep and feet that develop footrot.

Authors:  Rachel Clifton; Emma M Monaghan; Martin J Green; Kevin J Purdy; Laura E Green
Journal:  Sci Rep       Date:  2022-05-27       Impact factor: 4.996

Review 2.  The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts.

Authors:  Timur Liwinski; Melina Heinemann; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2022-05-10       Impact factor: 11.759

3.  Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease.

Authors:  Jonas Ghyselinck; Lynn Verstrepen; Frédéric Moens; Pieter Van Den Abbeele; Arnout Bruggeman; Jawal Said; Barry Smith; Lynne Ann Barker; Caroline Jordan; Valentina Leta; K Ray Chaudhuri; Abdul W Basit; Simon Gaisford
Journal:  Int J Pharm X       Date:  2021-07-02

4.  Host phenotype classification from human microbiome data is mainly driven by the presence of microbial taxa.

Authors:  Renato Giliberti; Sara Cavaliere; Italia Elisa Mauriello; Danilo Ercolini; Edoardo Pasolli
Journal:  PLoS Comput Biol       Date:  2022-04-21       Impact factor: 4.475

5.  Perspective: Leveraging the Gut Microbiota to Predict Personalized Responses to Dietary, Prebiotic, and Probiotic Interventions.

Authors:  Sean M Gibbons; Thomas Gurry; Johanna W Lampe; Anirikh Chakrabarti; Veerle Dam; Amandine Everard; Almudena Goas; Gabriele Gross; Michiel Kleerebezem; Jonathan Lane; Johanna Maukonen; Ana Lucia Barretto Penna; Bruno Pot; Ana M Valdes; Gemma Walton; Adrienne Weiss; Yoghatama Cindya Zanzer; Naomi V Venlet; Michela Miani
Journal:  Adv Nutr       Date:  2022-10-02       Impact factor: 11.567

6.  A Machine Learning Approach to Study Glycosidase Activities from Bifidobacterium.

Authors:  Carlos Sabater; Lorena Ruiz; Abelardo Margolles
Journal:  Microorganisms       Date:  2021-05-11

7.  5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease.

Authors:  Vipul Yadav; Yang Mai; Laura E McCoubrey; Yasufumi Wada; Motoyasu Tomioka; Satofumi Kawata; Shrikant Charde; Abdul W Basit
Journal:  Biomedicines       Date:  2021-05-20

Review 8.  Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases.

Authors:  Ting-Wei Kao; Chin-Chou Huang
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

9.  Machine Learning Predicts Drug Metabolism and Bioaccumulation by Intestinal Microbiota.

Authors:  Laura E McCoubrey; Stavriani Thomaidou; Moe Elbadawi; Simon Gaisford; Mine Orlu; Abdul W Basit
Journal:  Pharmaceutics       Date:  2021-11-25       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.